Study S001962

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); (ELEVATE-LIVER)

ClinicalTrials.gov record

Registration

Registration: NCT07850063
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 600
Start: 2026-10-23
Primary completion: 2029-04-29
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions: COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo matching survodutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:1111-1339-5364; REGISTRY:2026-527091-88-00

Registered primary outcomes

Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters [At week 76]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.